APOC3 and fatty liver disease: This discovery unveils a potential novel molecular target for therapeutic strategies against hepatic steatosis during the aging process, offering insights into its molecular and cellular underpinnings, particularly its association with FoxO6-mediated ApoC3 upregulation.